Neuropsychopharmacology Reports最新文献

{"title":"Clinical Characteristics of Patients With Cannabis-Related Mental Disorders and an Examination of Factors Influencing Their Access to Medical and Nonmedical Resources: Comparison of Methamphetamine-Related Mental Disorders.","authors":"Toshihiko Matsumoto, Takashi Usami, Akiho Nishimura, Sayako Higuchi, Kyoji Okita, Takuya Shimane","doi":"10.1002/npr2.70051","DOIUrl":"10.1002/npr2.70051","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to identify the characteristics of patients with cannabis use disorder and to determine whether the challenges in treating cannabis use disorder stem from the pharmacological properties of cannabis as an abused substance or from other contributing factors.</p><p><strong>Methods: </strong>The subjects of this study were the 208 male cases of methamphetamine-related mental disorders (MAP group) and 82 male cases of cannabis-related mental disorders (CAN group), which drawn from the \"2024 Nationwide Survey on the Actual Conditions of Drug-Related Mental Disorders in Psychiatric Hospitals in Japan.\" Clinical variables were compared between the two groups, and logistic regression analyses were conducted to examine the use of medical and nonmedical resources.</p><p><strong>Results: </strong>The CAN group was found to be younger, to have fewer histories of drug-related criminal offenses, incarceration in correctional facilities, or comorbid psychiatric disorders, compared to the MAP group, and to exhibit less severe forms of substance use disorder and have less experience participating in self-help groups or utilizing private recovery support facilities. Logistic regression analyses of the use of self-help groups and private recovery support facilities indicated that the utilization of these nonmedical resources was more strongly associated with older age and greater severity of substance use disorder than with the specific type of substance abused.</p><p><strong>Conclusion: </strong>Recently, an increasing number of young patients in Japan have been arrested for cannabis-related offenses and seek addiction treatment. There is growing concern that current nonmedical support resources may not adequately address the specific needs of these individuals.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 3","pages":"e70051"},"PeriodicalIF":2.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12449738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amelioration of Adults' Mental Health Conditions and Symptoms Through Spiritual Energy Therapy: Randomized Controlled Trial.","authors":"Mahendra Kumar Trivedi, Alice Branton, Dahryn Trivedi, Sambhu Mondal, Snehasis Jana","doi":"10.1002/npr2.70050","DOIUrl":"10.1002/npr2.70050","url":null,"abstract":"<p><p>Reduced physical activities, social support, old age, and increased exposure to regular stressful life events are crucial factors for poor mental health. Although several medicines are available to support mental health-related symptoms, due to more side effects and non-compliance for long-term use, these conventional medicines are not appropriate to tackle these symptoms. In this context, the study aimed to determine whether spiritual energy therapy with an experienced spiritual energy practitioner could manage adults' psychological and mental health-related symptoms. A single-blind, active-controlled, randomized trial was performed. Enrolled participants (n = 80) exhibited at least one psychological symptom. Spiritual energy therapy was given to subjects at two time points (Days 0 and 90) in physical presence. Psychological scores and physiological biomarkers were assessed. Treatment group subjects were reported to have a significant (p ≤ 0.0001) improvement in psychological scores related to stress, depression, mental restlessness, emotional trauma, hopelessness, etc., compared to the control group subjects. Additionally, subjects in the treatment group also showed significant improvement in biological markers compared to those in the control group. No treatment-related adverse effects were observed. The current study data unveiled a significant effect of spiritual energy therapy on improving adults' mental health conditions and symptoms, and significantly decreased elevated proinflammatory and oxidative stress biomarker levels in the treatment group.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 3","pages":"e70050"},"PeriodicalIF":2.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12422956/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clarifying the Gateway Hypothesis and Conflict of Interest in Cannabis Research.","authors":"Kenjiro Shiraishi","doi":"10.1002/npr2.70056","DOIUrl":"10.1002/npr2.70056","url":null,"abstract":"<p><p>This image visualizes the weighing of commercial incentives against research integrity, highlighting the challenge of maintaining transparency in CBD-related studies.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 3","pages":"e70056"},"PeriodicalIF":2.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12420910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145029655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Lemborexant-Based Sleep Medication Formulary on Benzodiazepine Reduction and Clinical Outcomes: A Single-Center Retrospective Study.","authors":"Shunya Aoki, Katsutoshi Takada, Tatsuru Sugama, Mitsugi Kimiwada, Tatsuya Hoshino, Kaori Koike, Hirokazu Akada, Takahisa Saiga, Shigeki Sato, Ryosuke Shinkai, Yukihiro Shibata, Takashi Tomita","doi":"10.1002/npr2.70054","DOIUrl":"10.1002/npr2.70054","url":null,"abstract":"<p><p>Benzodiazepine and non-benzodiazepine hypnotics (Z-drugs) are known risk factors for adverse events, including delirium and falls. Although formularies are intended to promote appropriate prescribing, few comprehensive studies have assessed their clinical impact in the context of sleep medications. This study aimed to evaluate changes in hypnotic prescribing patterns and associated clinical outcomes following the implementation of a sleep medication formulary. A psychiatric liaison team developed and implemented a formulary in April 2024, recommending lemborexant as the first-line treatment and eszopiclone as the second-line option. This single-center, retrospective study compared patients admitted and discharged during the 12 months before (April 2023 to March 2024; n = 12 633) and after (April 2024 to March 2025; n = 12 931) implementation. Outcome measures included monthly prescription volumes, diazepam equivalents, use in clinical pathways and prescription sets, delirium incidence, nighttime falls, and length of hospital stay. Statistical analyses were performed using the Mann-Whitney U-test and Fisher's exact test. Following implementation, prescription volumes of lemborexant and eszopiclone increased significantly, whereas diazepam equivalents decreased from 10 682 mg to 4117 mg. All 104 clinical pathways and prescription sets previously using benzodiazepine hypnotics or Z-drugs were converted to lemborexant. Monthly delirium cases declined from 12.5 to 8.0, and the proportion of nighttime falls among patients receiving benzodiazepine hypnotics or Z-drugs decreased from 24.0% to 11.5%. The median hospital stay also decreased from 8 to 7 days. These findings suggest that formulary implementation effectively optimized hypnotic prescribing and contributed to improved clinical outcomes and patient safety in an acute care setting.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 3","pages":"e70054"},"PeriodicalIF":2.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12416910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to \"Clinical Characteristics of Patients With Enlarged Ventricles and Cognitive Impairment (EVCI): Case Series\".","authors":"","doi":"10.1002/npr2.70058","DOIUrl":"10.1002/npr2.70058","url":null,"abstract":"","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 3","pages":"e70058"},"PeriodicalIF":2.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12436025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reporting Frequency of Antipsychotics-Induced Tardive Dyskinesia and Other Extrapyramidal Symptoms: Analysis Based on a Spontaneous Reporting System Database in Japan.","authors":"Yosuke Saga, Hiroshi Horio, Chih-Lin Chiang, Akihide Wakamatsu","doi":"10.1002/npr2.70049","DOIUrl":"10.1002/npr2.70049","url":null,"abstract":"<p><p>First- and second-generation antipsychotics (FGAs and SGAs, respectively) with dopamine-antagonizing properties may cause involuntary movement-related adverse drug reactions (ADRs). However, the risk in the Japanese population is not well characterized. In this study, we analyzed spontaneous ADR reports from the Japanese Adverse Drug Event Report (JADER) database and evaluated the reporting odds ratios (RORs) of tardive dyskinesia (TD) and other extrapyramidal symptoms (EPS) associated with antipsychotics. SGAs were evaluated both as a whole class and as subgroups based on their primary pharmacological mode of action. From 1 April 2011 to 31 March 2020, 1 197 065 ADRs, including 760 TD and 6059 EPS cases, were identified for this study. By calculating RORs, risk signals were detected with both FGAs and SGAs for TD and EPS compared with non-antipsychotics, with an ROR (95% confidence interval (CI)) of 153.9 (125.64-188.34) with FGAs for TD and 95.3 (80.61-112.65) with SGAs total for TD. No risk signals were detected for SGAs total data or any SGA subgroups versus FGAs. The ROR (95% CI) with SGAs total versus FGAs for TD was 0.62 (0.51-0.75), for dyskinesia: 0.55 (0.42-0.72), and for parkinsonism: 0.43 (0.35-0.52), showing that SGAs were associated with lower reporting frequency versus FGAs, but not for akathisia and dystonia. In conclusion, both FGAs and SGAs were associated with risks for TD and EPS compared with non-antipsychotics in the Japanese population, and SGAs total or all SGA subgroups showed no risk signals compared with FGAs.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 3","pages":"e70049"},"PeriodicalIF":2.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12426896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonrandomized Allocation of Steroid Therapy in Patients With Fukuyama Congenital Muscular Dystrophy: Study Protocol for a Phase II Clinical Trial.","authors":"Terumi Murakami, Takatoshi Sato, Takami Ishizuka, Harumasa Nakamura, Hisateru Tachimori, Hiroko Harada, Hideki Oi, Kenji Hatano, Mari S Oba, Kumiko Ishiguro, Minobu Shichiji, Yuki Kihara, Yasuhiro Takeshima, Mariko Taniguchi-Ikeda, Ayako Hattori, Yuko Shimizu-Motohashi, Hiroyuki Awano, Ryosuke Bo, Satoru Nagata, Keiko Ishigaki","doi":"10.1002/npr2.70043","DOIUrl":"10.1002/npr2.70043","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to evaluate the efficacy and safety of steroid therapy in patients with Fukuyama congenital muscular dystrophy (FCMD).</p><p><strong>Methods: </strong>This is a noncontrolled, nonblinded, multicenter collaborative phase 2 trial in patients with a definite diagnosis of 3-kb insertion mutation homozygous or compound heterozygous FCMD based on genetic testing. The first part of the study evaluates efficacy; patients with homozygous FCMD were given oral prednisolone at a dose of 1 mg/kg on alternate days (0.5 mg/kg/day) for 24 weeks. The second part of the study evaluates safety; patients with homozygous and heterozygous FCMD were given oral prednisolone at a dose of 1 mg/kg on alternate days (0.5 mg/kg/day) for 48 weeks. Homozygous patients will be evaluated in the first part of the study for up to 24 weeks after prednisolone administration, after which they will continue receiving prednisolone in the second part for an additional 24 weeks. The primary endpoints were the changes in motor function evaluated using the gross motor function measure after treatment with prednisolone in the first part and the safety profiles based on the results of physical examination, vital signs, 12-lead electrocardiography (ECG), echocardiography, ophthalmic testing, SpO₂, laboratory tests, immunological tests, and adverse events in the second part.</p><p><strong>Discussion: </strong>Based on previous clinical research, prednisolone shows great potential as a therapeutic drug in patients with FCMD. To achieve this goal, we planned an investigator-initiated trial to confirm the effectiveness and safety of prednisolone.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 3","pages":"e70043"},"PeriodicalIF":2.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacogenetic Considerations in Caffeine Toxicity: Insights Prompted by the \"Death Coffee\" Case Series.","authors":"Yuji Kamikubo","doi":"10.1002/npr2.70027","DOIUrl":"10.1002/npr2.70027","url":null,"abstract":"","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 2","pages":"e70027"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12138271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Augmentation Therapy With Serotonin 5-HT_1A Receptor Partial Agonists on Cognitive Function in Depressive Disorders: A Systematic Review of Randomized Controlled Studies.","authors":"Risa Yamada, Ayumu Wada, Andrew Stickley, Adrian Newman-Tancredi, Tomiki Sumiyoshi","doi":"10.1002/npr2.70023","DOIUrl":"10.1002/npr2.70023","url":null,"abstract":"<p><strong>Objective: </strong>The use of serotonin 5-HT_1A receptor partial agonists (5-HT_1A-PAs) as an add-on therapy has been associated with the enhancement of attention/processing speed in patients with schizophrenia. Also, 5-HT_1A receptors have been shown to play a role in the pathophysiology of mood disorders. There is compelling evidence supporting that stimulation of 5-HT_1A receptors accelerates antidepressant effects. Accordingly, this systematic review examines the ability of adjunctive treatment with 5-HT_1A-PAs to improve cognitive function in patients with depressive symptoms.</p><p><strong>Methods: </strong>A literature search using PubMed, the Cochrane Library, and Web of Science databases was performed from 1987 to January 2024 to identify randomized controlled trials (RCTs) corresponding to the following inclusion criteria: (1) RCTs, (2) human studies; studies that (3) targeted patients with a psychiatric disorder (except for schizophrenia or schizoaffective disorder), (4) evaluated the effect of cognitive functions, (5) were written in English.</p><p><strong>Results: </strong>From the 80 studies initially screened, three met the inclusion criteria. Two of these studies dealt with vascular depression while one focused on major depressive disorder (MDD). In MDD, combined treatment with buspirone and melatonin was more efficacious in ameliorating subjective cognitive disturbances compared to the use of buspirone alone or the use of a placebo. Likewise, the combination of escitalopram-tandospirone was more advantageous than escitalopram alone for improving executive function and verbal fluency in patients with vascular depression.</p><p><strong>Conclusions: </strong>Further studies with novel 5-HT_1A receptor agonists are warranted to examine their potentially more robust benefits on cognitive performance in subjects suffering from mood deficits.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 2","pages":"e70023"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107367/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Organic Arsenic Compound Diphenylarsinic Acid Transfers From the Mother to the Fetus via the Placenta in Mammals.","authors":"Tomoyuki Masuda, Kazuhiro Ishii, Tomohiro Nakayama, Nobuaki Iwasaki","doi":"10.1002/npr2.70025","DOIUrl":"10.1002/npr2.70025","url":null,"abstract":"<p><strong>Background: </strong>In 2003, contamination of drinking well water with diphenylarsinic acid (DPAA), an organoarsenic compound not naturally found in the environment, was reported in Kamisu City, Ibaraki Prefecture, due to suspected illegal dumping. Residents in the surrounding area, including pregnant women, were exposed to DPAA, leading to health issues primarily affecting the central nervous system. However, the extent of DPAA transfer from pregnant women to their fetuses remains unknown.</p><p><strong>Methods: </strong>The concentration of DPAA in preserved dried umbilical cords from pregnant women who had consumed DPAA-contaminated well water was measured using liquid chromatography-tandem mass spectrometry. Additionally, pregnant rats (n = 9) were orally administered DPAA (0.25, 0.5, or 1.0 mg/kg/day) for 13 days. Fetuses (five per mother, n = 45) were delivered, and the DPAA concentrations in maternal and fetal blood, as well as in the brain, were measured.</p><p><strong>Results: </strong>The DPAA concentration in fetal blood was 30.0%-40.1% of that in maternal blood, regardless of the administered dose. On the other hand, the DPAA concentration in the fetal brain was 8.31%-9.00% of that in the maternal brain, independent of the administered DPAA dose.</p><p><strong>Conclusion: </strong>The analysis of umbilical cords from pregnant women who drank water containing DPAA revealed that DPAA could transfer from the mother to the fetus through the placenta. Additionally, experiments using rodents confirmed that DPAA could also reach the fetal brain through placental transfer, but the transfer rate was low.</p>","PeriodicalId":19137,"journal":{"name":"Neuropsychopharmacology Reports","volume":"45 2","pages":"e70025"},"PeriodicalIF":2.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12104724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}